Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
USF Eye Institute
mi
from
Tampa, FL
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
USF Eye Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
University of Illinois at Chicago Medical Center
mi
from
Chicago, IL
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
University of Illinois at Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Northwestern University
mi
from
Evanston, IL
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Northwestern University
mi
from
Evanston, IL
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Northshore Eye and Vision Center
mi
from
Glenview, IL
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Northshore Eye and Vision Center
mi
from
Glenview, IL
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Midwest Eye Institute
mi
from
Indianapolis, IN
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Midwest Eye Institute
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Univ KY Clinical Resch Org- KY Clinic
mi
from
Lexington, KY
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Univ KY Clinical Resch Org- KY Clinic
mi
from
Lexington, KY
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Paducah Retinal Center
mi
from
Paducah, KY
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Paducah Retinal Center
mi
from
Paducah, KY
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Bethesda Neurology, LLC
mi
from
Bethesda, MD
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Bethesda Neurology, LLC
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Longwood Medical Eye Center
mi
from
Boston, MA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Longwood Medical Eye Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Atlantic Clinical Trials, Llc
mi
from
Watertown, MA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Atlantic Clinical Trials, Llc
mi
from
Watertown, MA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Henry Ford Health System
mi
from
Dearborn, MI
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Henry Ford Health System
mi
from
Dearborn, MI
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Neuro-Ophthalmic Services
mi
from
Royal Oak, MI
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Neuro-Ophthalmic Services
mi
from
Royal Oak, MI
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
University of Minnesota Medical School
mi
from
Minneapolis, MN
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
University of Minnesota Medical School
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
JFK Medical Center, NJ Neuroscience Institute
mi
from
Edison, NJ
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
JFK Medical Center, NJ Neuroscience Institute
mi
from
Edison, NJ
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Stony Brook University Medical Center
mi
from
East Setauket, NY
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Stony Brook University Medical Center
mi
from
East Setauket, NY
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
E.S. Harkness Eye Institute
mi
from
New York, NY
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
E.S. Harkness Eye Institute
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Pmg Research Of Salisbury
mi
from
Salisbury, NC
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Pmg Research Of Salisbury
mi
from
Salisbury, NC
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
The Ohio State University College of Medicine
mi
from
Columbus, OH
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
The Ohio State University College of Medicine
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Dr. Daniel Lin
mi
from
Oregon, OH
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Dr. Daniel Lin
mi
from
Oregon, OH
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Family Eye Care
mi
from
Lancaster, PA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Family Eye Care
mi
from
Lancaster, PA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
University of Pennsylvania Hospital
mi
from
Philadelphia, PA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
University of Pennsylvania Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Allegheny Ophthalmic and Orbital Associates
mi
from
Pittsburgh, PA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Allegheny Ophthalmic and Orbital Associates
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Retina Consultants of Charleston
mi
from
Charleston, SC
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Retina Consultants of Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Black Hills Regional Eye Institute
mi
from
Rapid City, SD
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Black Hills Regional Eye Institute
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Neuro-Opthalmology of Texas
mi
from
Houston, TX
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Neuro-Opthalmology of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
University of Washington Medical Center
mi
from
Seattle, WA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Swedish Neuroscience Institute
mi
from
Seattle, WA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Swedish Neuroscience Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Saint Louis University
mi
from
Saint Louis, MO
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Montefiore Medical Center
mi
from
The Bronx, NY
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
RCT: Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury
RCT Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury
Status: Enrolling
Updated:  9/5/2017
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
RCT: Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury
RCT Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury
Status: Enrolling
Updated: 9/5/2017
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
RCT: Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury
RCT Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury
Status: Enrolling
Updated:  9/5/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
RCT: Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury
RCT Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury
Status: Enrolling
Updated: 9/5/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
RCT: Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury
RCT Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury
Status: Enrolling
Updated:  9/5/2017
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
RCT: Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury
RCT Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury
Status: Enrolling
Updated: 9/5/2017
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Hope Research Institute Medical Plaza LLC Desert Hills
mi
from
Phoenix, AZ
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Hope Research Institute Medical Plaza LLC Desert Hills
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Multiple Sclerosis Center Drive, Neurology Suite 701
mi
from
Newport Beach, CA
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Multiple Sclerosis Center Drive, Neurology Suite 701
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
University of Colorado at Denver Health and Sciences
mi
from
Denver, CO
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
University of Colorado at Denver Health and Sciences
mi
from
Denver, CO
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Fort Collins Neurology
mi
from
Fort Collins, CO
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Fort Collins Neurology
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
MS Center of Brevard MIMA Centry Research Associates
mi
from
Melbourne, FL
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
MS Center of Brevard MIMA Centry Research Associates
mi
from
Melbourne, FL
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
University of South Florida
mi
from
Tampa, FL
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
MS Center of Atlanta
mi
from
Atlanta, GA
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
MS Center of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Bruce Hughes West Building
mi
from
Des Moines, IA
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Bruce Hughes West Building
mi
from
Des Moines, IA
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Research Site
mi
from
Rockland, MA
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Research Site
mi
from
Rockland, MA
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Michigan Neurology Associates P.C.
mi
from
Clinton, MI
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Michigan Neurology Associates P.C.
mi
from
Clinton, MI
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Henry Ford Hospital
mi
from
Detroit, MI
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Dennis Dietrich
mi
from
Great Falls, MT
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Dennis Dietrich
mi
from
Great Falls, MT
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
University of Medicine and Dentistry of New Jersey School of Neurology
mi
from
Stratford, NJ
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
University of Medicine and Dentistry of New Jersey School of Neurology
mi
from
Stratford, NJ
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Upstate Clinical Research LLC 3
mi
from
Albany, NY
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Upstate Clinical Research LLC 3
mi
from
Albany, NY
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Neurological Specialists of Long Island
mi
from
Great Neck, NY
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Neurological Specialists of Long Island
mi
from
Great Neck, NY
Click here to add this to my saved trials